Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia

By sjmartinez • March 7, 2023

Kreitman RJ, Moreau P, Ravandi F, Hutchings M, Gazzah A, Michallet AS, Wainberg ZA, Stein A, Dietrich S, de Jonge MJA, Willenbacher W, De Grève J, Arons E, Ilankumaran P, Burgess P, Gasal E, Subbiah V. Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia. Blood. 2023 Mar 2;141(9):996-1006. doi: 10.1182/blood.2021013658. PMID: 36108341.

Tags: Hematology/Oncology, Publications

Galectin-1 modulates glycolysis via a GM1-galactose-dependent pathway to promote hyperthermia resistance in hepatocellular carcinoma

Nguyen T, Shin Y, Ruppa A, Krall AS, Pham J, Chen PC, Mirmohammadi H, Keshavarz P, Finn RS, Agopian VG, French SW, Christofk HR, Lu[...]

Treatment Patterns of Goserelin 3.6 mg Once Every 4 Weeks and 10.8 mg Once Every 12 Weeks in Women With Breast Cancer: A Real-World Analysis of Patients in the United States

McCann KE, Kaklamani V, Osman N, Cannon J, Brent L, Lucia R, Li C, Duran N, Gupta S, Martin N. Treatment Patterns of Goserelin 3.6[...]

Neoadjuvant Chemotherapy Is Associated With Reduced Amputation Risk in Synovial Sarcoma of the Lower Extremity

Wahle CF, Newman-Hung NJ, Sakowitz S, Federman N, Singh AS, Bernthal NM, Benharash P, Wessel LE. Neoadjuvant Chemotherapy Is Associated With Reduced Amputation Risk in[...]